Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

Dr. French's research focuses on a deadly cancer of children and young adults called NUT midline carcinoma. A while back Dr. French discovered the cancer protein that causes this disease, called BRD4-NUT. This discovery led to the development of inhibitors to BRD4 that are now being used to treat NUT midline carcinoma and this has expanded to the treatment of more common cancers in clinical trials. However, NUT midline carcinoma remains incurable. Recently, Dr. French discovered an additional and completely new protein that associates with BRD4-NUT, called a ZNF532, that helps BRD4-NUT cause this cancer. This research aims to understand how this new cancer protein contributes to the malignancy in this disease.

Modern therapies such as stem cell transplant and immune therapy have made high-risk neuroblastoma a survivable disease for some children, but little is known about the chronic health issues experienced by survivors. In order to ensure that future treatments address both the chance and the quality of cure, this consortium aims to examine the impact of neuroblastoma therapy on survivors' growth, pubertal development and long-term health. This grant is generously supported by the "Just Do It...…and be done with it" Hero Fund created in honor of Sara Martorano who doesn't let anything dim her sparkle and has a compassionate heart and smile. It also celebrates the courage of all cancer kids through treatment and the support of their family and friends.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Late Effects After High Risk Neuroblastoma – The LEAHRN Study. For a description of this project, see the consortium grant made to the lead institution: University of Chicago, Chicago, IL

This institution is a member of a research consortium which is being funded by St. Baldrick's: Late Effects After High Risk Neuroblastoma – The LEAHRN Study. For a description of this project, see the consortium grant made to the lead institution: University of Chicago, Chicago, IL

This institution is a member of a research consortium which is being funded by St. Baldrick's: Late Effects After High Risk Neuroblastoma – The LEAHRN Study. For a description of this project, see the consortium grant made to the lead institution: University of Chicago, Chicago, IL

This institution is a member of a research consortium which is being funded by St. Baldrick's: Late Effects After High Risk Neuroblastoma – The LEAHRN Study. For a description of this project, see the consortium grant made to the lead institution: University of Chicago, Chicago, IL

This institution is a member of a research consortium which is being funded by St. Baldrick's: Late Effects After High Risk Neuroblastoma – The LEAHRN Study. For a description of this project, see the consortium grant made to the lead institution: University of Chicago, Chicago, IL

This institution is a member of a research consortium which is being funded by St. Baldrick's: Late Effects After High Risk Neuroblastoma – The LEAHRN Study. For a description of this project, see the consortium grant made to the lead institution: University of Chicago, Chicago, IL